Oncolytics Biotech (ONCY) Change in Working Capital (2009 - 2025)

Oncolytics Biotech (ONCY) has reported Change in Working Capital for 17 consecutive years, with $1.9 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Change in Working Capital fell 40.56% year-over-year to $1.9 million; the TTM figure through Sep 2025 stood at $442259.6 (down 89.99% YoY), while the FY2024 annual figure was $2.6 million, up 97.54% from the prior year.
• Change in Working Capital grew to $1.9 million in Q3 2025 per ONCY's latest filing, from -$155889.9 in the prior quarter.
• Across five years, Change in Working Capital topped out at $3.2 million in Q3 2024 and bottomed at -$1.4 million in Q2 2023.
• Historically, Change in Working Capital has averaged $312988.3 across 5 years, with a median of -$24489.7 in 2024.
• Annual changes were most pronounced in 2021 — Change in Working Capital surged 39497.82% — and 2025, when it sank 2330.27%.
• Oncolytics Biotech's Change in Working Capital stood at $1.3 million in 2021, then gained by 1.47% to $1.4 million in 2022, then dropped by 17.31% to $1.1 million in 2023, then sank by 161.31% to -$687215.2 in 2024, then jumped by 373.65% to $1.9 million in 2025.
• Business Quant data shows ONCY's Change in Working Capital at $1.9 million in Q3 2025, -$155889.9 in Q2 2025, and -$595166.7 in Q1 2025.